Literature DB >> 16319517

Expression of tumor necrosis factor alpha and matrix metalloproteinase-9 in surgically induced necrotizing scleritis.

Kyoung Yul Seo1, Hyung Keun Lee, Eung Kweon Kim, Joon H Lee.   

Abstract

BACKGROUND: Surgically induced necrotizing scleritis is primarily managed with immunosuppressive regimens. Such treatments can alter inflammatory cytokines and products such as tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-9 (MMP-9), which are an important proinflammatory cytokine and a tissue-degrading protease involved in necrosis of some ocular tissues. OBJECT: To evaluate TNF-alpha and MMP-9 in the tear or sclera of surgically induced necrotizing scleritis.
METHODS: After tear collection from healthy and diseased eyes of 2 patients, immunoblot analysis using monoclonal antibody specific for human TNF-alpha and MMP-9 was performed. In another patient, scleral tissues were obtained during scleral allograft surgery, and the same immunoblot analysis was done.
RESULTS: The level of TNF-alpha and MMP-9 was increased in tear fluid from patients compared to that of control volunteers and returned to the control level after treatment. The diseased sclera showed an increased expression of MMP-9 compared to that of the normal donor sclera.
CONCLUSIONS: TNF-alpha and MMP-9 may suggest disease activity of surgically induced necrotizing scleritis and can be altered by proper immunosuppressive treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319517     DOI: 10.1159/000090010

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  4 in total

1.  Rapid Regression of Scleral Melting Associated with Tumor Necrosis Factor-α in a Case of Surgically Induced Necrotizing Scleritis.

Authors:  Norihiko Misawa; Mizuki Tagami; Atsushi Sakai; Takeya Kohno; Shigeru Honda
Journal:  Case Rep Ophthalmol       Date:  2020-08-06

2.  Infliximab for the treatment of active scleritis.

Authors:  H Nida Sen; Amit Sangave; Keri Hammel; Grace Levy-Clarke; Robert B Nussenblatt
Journal:  Can J Ophthalmol       Date:  2009-06       Impact factor: 1.882

3.  Bilateral anterior and posterior scleritis in a patient with acute myelogenous leukemia.

Authors:  Pujan R Patel; Maureen C Farrell; Ani Peshtani; Meghan K Berkenstock
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-24

4.  Acute sclerokeratitis after cataract surgery: treatment with topical use of cyclosporine - a.

Authors:  K Doulas; C Pantazopoulou; D Feretis
Journal:  Open Ophthalmol J       Date:  2008-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.